Tern Plc publishes presentations from Device Authority and Talking Medicines investor event

TERN

Tern Plc (LON:TERN), the investment company specialising in supporting high growth, early-stage, disruptive Internet of Things technology businesses, has announced that following its online presentation and a Q&A session yesterday evening involving Tern’s portfolio companies Device Authority and Talking Medicines, copies of the presentations from the participating companies can be found via the links below:

Device Authority presentation:  

Talking Medicines presentation:

In addition a recording of the event will shortly be available to view on Tern plc’s website at: https://www.ternplc.com/resources

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Talking Medicines targets better pharmaceutical launch results through message analysis

Talking Medicines' Message Resonance Score measures doctors' understanding of pharmaceutical messaging to help companies improve launch strategies.

Device Authority addresses security risks as AI takes control of physical machines

Device Authority's KeyScaler platform supports secure AI-driven automation by helping organisations authenticate connected machines, protect device identities and control access to physical equipment.

Talking Medicines examines factors influencing prescribing decisions

Talking Medicines explains how healthcare professional conversations, clinical considerations and treatment perceptions can provide pharmaceutical companies with deeper insight into prescribing intent beyond traditional campaign metrics.

What HCPs say could reveal prescribing intent

Talking Medicines is using AI to analyse HCP conversations and identify the clinical and practical factors that may influence prescribing intent.

AI control of machines raises new security questions

AI is gaining the ability to control physical equipment, but establishing that machines are genuine, authorised and secure will be an important part of making this technology safe to deploy.

CAR-T therapy brings new approach to multiple myeloma treatment

CAR-T therapy is being used in multiple myeloma and is being studied earlier in the treatment pathway, with research focused on improving durability, safety and access.

Search